Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial for Newly Diagnosed Low-risk Multiple Myeloma Patients Comparing 6 Cycles of Isatuximab With Lenalidomide/Bortezomib/Dexamethasone (I-VRD) Compared to 3 Cycles of I-VRD Followed by One Cycle of High-dose Therapy and Both Arms Followed by Maintenance Therapy With I-R.

NCT05665140 is registered in ClinicalTrials.gov with University Hopsital Schleswig Holstein Campus Lübeck as lead sponsor.

NCT NCT05665140
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05665140 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial for Newly Diagnosed Low-risk Multiple Myeloma Patients Comparing 6 Cycles of Isatuximab With Lenalidomide/Bortezomib/Dexamethasone (I-VRD) Compared to 3 Cycles of I-VRD Followed by One Cycle of High-dose Therapy and Both Arms Followed by Maintenance Therapy With I-R.
Lead sponsor
University Hopsital Schleswig Holstein Campus Lübeck
Phase
Phase 2/3
Overall status
Recruiting
Start date
February 3, 2023
Completion date
October 31, 2028
Enrollment
100 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

newly diagnosed multiple myeloma